| Sep 4 2024 |
FDA Continues to Intentionally Incorporate AI into Medical Product Development with Its Establishment of a New Internal Advisory Body |
Mintz |
| Sep 4 2024 |
This Week in 340B: August 27 – September 2, 2024 |
McDermott Will & Emery |
| Sep 3 2024 |
DEA Announces December Hearing on Proposal to Reschedule Marijuana |
ArentFox Schiff LLP |
| Sep 3 2024 |
DOL: Indefinite Delay in FLAG System Update for New H-2A Farmworker Visa Rule |
Jackson Lewis P.C. |
| Sep 3 2024 |
California School Food Dye Ban Approved by Legislature |
Keller and Heckman LLP |
| Sep 3 2024 |
The 340B ‘Saga’ Continues: As More States Pass 340B Contract Pharmacy Laws, More Lawsuits Follow |
ArentFox Schiff LLP |
| Sep 3 2024 |
Update: OHCA Approves Amendments to Cost and Market Impact Review (CMIR) Regulations |
Sheppard, Mullin, Richter & Hampton LLP |
| Sep 3 2024 |
Brussels Regulatory Brief: Summer 2024 |
K&L Gates LLP |
| Sep 3 2024 |
Unpacking Averages: How Old Are Medical Devices on the US Market? |
Epstein Becker & Green, P.C. |
| Aug 30 2024 |
Maine Updates Ownership Disclosure Requirements |
McDermott Will & Emery |
| Aug 30 2024 |
Major Changes Coming for Medicare Drug Program: Negotiated Prices, Cap on Out of Pocket and Creditable Coverage |
Norris McLaughlin P.A. |
| Aug 30 2024 |
USDA Releases Updated Guideline Regarding Animal-Raising and Environment-Related Claims on Meat and Poultry |
Keller and Heckman LLP |
| Aug 30 2024 |
EPA Finalizes Novel Herbicide Strategy to Protect Endangered Species |
Beveridge & Diamond PC |
| Aug 29 2024 |
Key Elements of an AI Governance Program in Healthcare |
Sheppard, Mullin, Richter & Hampton LLP |
| Aug 29 2024 |
2024 CPSC and FDA Enforcement Trends |
Foley & Lardner LLP |
| Aug 29 2024 |
Litigation Against Pharmacy Benefit Managers |
Young Law Group |
| Aug 29 2024 |
FDA to End MOU with AAFCO – Impact on Animal Food Ingredient Review |
Keller and Heckman LLP |
| Aug 29 2024 |
Why are TSCA Citizen Petitions Filed? — A Conversation with Michael Connett [Podcast] |
Bergeson & Campbell, P.C. |
| Aug 28 2024 |
This Week in 340B: August 20 – 26, 2024 |
McDermott Will & Emery |
| Aug 28 2024 |
APHIS Issues Regulatory Status Review Responses to University of Florida and Bioceres Crop Solutions |
Bergeson & Campbell, P.C. |
| Aug 28 2024 |
FDA Issues Warning Letter to Manufacturer of Lead-Contaminated Apple Cinnamon Products |
Keller and Heckman LLP |
| Aug 27 2024 |
Ready-to-Drink Cocktail Permits: Ready to Go in Pennsylvania |
Norris McLaughlin P.A. |
| Aug 27 2024 |
Judge Blocks New DOL H-2A Farmworker Visa Rule in 17 States |
Jackson Lewis P.C. |
| Aug 27 2024 |
PCRM NURA Program Will Hold Webinar Series on Human-Based Methods in FDA Submissions |
Bergeson & Campbell, P.C. |
| Aug 27 2024 |
China Proposed New Anti-Monopoly Guidelines for the Pharmaceutical Sector |
Sheppard, Mullin, Richter & Hampton LLP |
| Aug 27 2024 |
The Broad Impact of Edwards v. Meril on the Safe Harbor Provision |
Proskauer Rose LLP |
| Aug 27 2024 |
Biotech Company Settles with Three State AGs Over Security Practices |
Sheppard, Mullin, Richter & Hampton LLP |
| Aug 27 2024 |
Mondelēz Sued for Deceptive Cocoa Sustainability Labeling |
Keller and Heckman LLP |
| Aug 27 2024 |
Cannabis Businessman Learns the Perils of the Not-So “Fine Print” – A Sobering Lesson For Us All |
Bradley Arant Boult Cummings LLP |
| Aug 26 2024 |
2024 Pre-Election Analysis: Health Care Issues |
Mintz |
| Aug 26 2024 |
China Releases Draft Guidelines for Front-of-Pack Nutrition Labeling |
Keller and Heckman LLP |
| Aug 26 2024 |
The Bright Side of the Road: FDA Decision on MDMA Leaves Psychedelic Therapy Down, Far From Out |
Bradley Arant Boult Cummings LLP |
| Aug 23 2024 |
EPA Bans the Use of DCPA |
Norris McLaughlin P.A. |
| Aug 23 2024 |
HHS-OIG Highlights Fraud, Abuse Concerns With Manufacturer Offering Financial Assistance to Treat Infertility Side Effects |
Barnes & Thornburg LLP |
| Aug 22 2024 |
NASEM Will Hold Virtual Town Hall on September 5 as Part of Its Quadrennial Review of the NNI |
Bergeson & Campbell, P.C. |
